Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non–small cell lung cancer
- 21 August 2025
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 208, 108716
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- Roche
- Micropalaeontological Society
This publication has 82 references indexed in Scilit:
- 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)Annals of Oncology, 2024
- Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective studyCancer Communications, 2024
- Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung CancerJAMA, 2024
- Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trialAnnals of Oncology, 2023
- TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosisJournal of Cancer Research and Clinical Oncology, 2023
- Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2Clinical Lung Cancer, 2023
- ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerAnnals of Oncology, 2022
- Category of evidence and consensus underlying National Comprehensive Cancer Network guidelines: Is there evidence of progress?International Journal of Cancer, 2020
- The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-AnalysisThe Annals of Thoracic Surgery, 2019
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996